Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-009 in Adult Patients With Metastatic Colorectal Cancer
NCT05513742Phase 2Completed
- Sponsor
- Compass Therapeutics, Inc.
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tovecimig in colorectal cancer (CRC), sponsored by Compass Therapeutics, Inc. Primary endpoint: Overall Response Rate at 16 weeks. Started Dec 2022; status: completed.
02
Drugs
tovecimig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05513742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513742.